Marine n3 polyunsaturated fatty acids enhance resistance to mitochondrial permeability transition in heart failure but do not improve survival

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 1, 2013, Pages

  Galvao, Tatiana F ^a,b   Khairallah, Ramzi J ^a   Dabkowski, Erinne R ^a   Brown, Bethany H ^a   Hecker, Peter A ^a   O'Connell, Kelly A ^a   O'Shea, Karen M ^a   Sabbah, Hani N ^c   Rastogi, Sharad ^c   Daneault, Caroline ^d   Rosiers, Christine Des ^d   Stanley, William C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c HENRY FORD HOSPITAL   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Cardiomyopathy; Diet; Fish oil; Metabolism; Mitochondria

Indexed keywords

CALCIUM ION; DELTA SARCOGLYCAN; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALORIC INTAKE; CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME SUBSTRATE; HAMSTER; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; MALE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; SARCOLEMMA; SURVIVAL TIME; TREATMENT DURATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOPTOSIS; CALCIUM; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; CRICETINAE; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; HEART FAILURE; MALE; MITOCHONDRIA, HEART; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCYTES, CARDIAC; OXIDATIVE PHOSPHORYLATION; PHOSPHOLIPIDS; SARCOGLYCANS; STROKE VOLUME; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84871852147     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00657.2012     Document Type: Article

References (47)

1. Abel ED, Doenst T. Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc Res 90: 234-242, 2011.
2. Barakat H, Brown W, Henry SD. Studies of fatty acid oxidation in homogenates of the cardiomyopathic hamster. Life Sci 23: 1835-1840, 1978.
3. Chen J, Shearer GC, Chen Q, Healy CL, Beyer AJ, Nareddy VB, Gerdes AM, Harris WS, O'Connell TD, Wang D. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 123: 584-593, 2011.
4. D'Hahan N, Taouil K, Dassouli A, Morel JE. Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6. Eur J Pharmacol 328: 163-174, 1997.
5. Dabkowski ER, Williamson CL, Hollander JM. Mitochondria-specific transgenic overexpression of phospholipid hydroperoxide glutathione peroxidase (GPx4) attenuates ischemia/reperfusion-associated cardiac dysfunction. Free Radic Biol Med 45: 855-865, 2008.
6. 2+ in hearts of cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol 264: H2188-H2197, 1993.
7. Duda MK, O'Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, Hoit BD, Kop WJ, Stanley WC. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res 76: 303-310, 2007.
8. Duda MK, O'Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, Chess DJ, Azimzadeh AM, Harris WS, Sharov VG, Sabbah HN, Stanley WC. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res 81: 319-327, 2009.
9. Fedor D, Kelley DS. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 12: 138-146, 2009.
10. Fiaccavento R, Carotenuto F, Minieri M, Masuelli L, Vecchini A, Bei R, Modesti A, Binaglia L, Fusco A, Bertoli A, Forte G, Carosella L, Di NP. Alpha-linolenic acid-enriched diet prevents myocardial damage and expands longevity in cardiomyopathic hamsters. Am J Pathol 169: 1913-1924, 2006.
11. Galvao TF, Brown BH, Hecker PA, O'Connell KA, O'Shea KM, Sabbah HN, Rastogi S, Daneault C, Des Rosiers C, Stanley WC. High intake of saturated fat, but not polyunsaturated fat, improves survival in heart failure despite persistent mitochondrial defects. Cardiovasc Res 93: 24-32, 2012.
12. Gelinas R, Thompson-Legault J, Bouchard B, Daneault C, Mansour A, Gillis MA, Charron G, Gavino V, Labarthe F, Des Rosiers C. Prolonged QT interval and lipid alterations beyond-oxidation in very long-chain acyl-CoA dehydrogenase null mouse hearts. Am J Physiol Heart Circ Physiol 301: H813-H823, 2011.
13. Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, Vriz O, Pasotti M, Gorini M, Marchioli R, Maggioni A, Tavazzi L. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail 12: 1345-1353, 2010.
14. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372: 1223-1230, 2008.
15. Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res 77: 334-343, 2008.
16. Halestrap AP. A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans 38: 841-860, 2010.
17. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 1787: 1402-1405, 2009.
18. Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A, Porter CB, Borkon AM. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 110: 1645-1649, 2004.
19. Hecker PA, Galvao TF, O'Shea KM, Brown BH, Henderson R Jr, Riggle H, Gupte SA, Stanley WC. High-sugar intake does not exacerbate metabolic abnormalities or cardiac dysfunction in genetic cardiomyopathy. Nutrition 28: 520-526, 2012.
20. Hikoso S, Ikeda Y, Yamaguchi O, Takeda T, Higuchi Y, Hirotani S, Kashiwase K, Yamada M, Asahi M, Matsumura Y, Nishida K, Matsuzaki M, Hori M, Otsu K. Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer. J Am Coll Cardiol 50: 453-462, 2007.
21. Hoppel CL, Tandler B, Parland W, Turkaly JS, Albers LD. Hamster cardiomyopathy: a defect in oxidative phosphorylation in the cardiac interfibrillar mitochondria. J Biol Chem 257: 1540-1548, 1982.
22. Igarashi M, Ma K, Chang L, Bell JM, Rapoport SI. Rat heart cannot synthesize docosahexaenoic acid from circulating alpha-linolenic acid because it lacks elongase-2. J Lipid Res 49: 1735-1745, 2008.
23. Javadov S, Huang C, Kirshenbaum L, Karmazyn M. NHE-1 inhibition improves impaired mitochondrial permeability transition and respiratory function during postinfarction remodelling in the rat. J Mol Cell Cardiol 38: 135-143, 2005.
24. Javadov S, Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem 20: 1-22, 2007.
25. Kako KJ, Thornton MJ, Heggtveit HA. Depressed fatty acid and acetate oxidation and other metabolic defects in homogenates from hearts of hamsters with hereditary cardiomyopathy. Circ Res 34: 570-580, 1974.
26. 2+-induced mitochondria permeability transition in normal and hypertrophied myocardium. J Pharmacol Exp Ther 335: 155-162, 2010.
27. Khairallah RJ, Sparagna GC, Khanna N, O'Shea KM, Hecker PA, Kristian T, Fiskum G, Des Rosiers C, Polster BM, Stanley WC. Dietary supplementation with docosahexaenoic acid, but not eicosapentaenoic acid, dramatically alters cardiac mitochondrial phospholipid fatty acid composition and prevents permeability transition. Biochim Biophys Acta 1797: 1555-1562, 2010.
28. Khairallah RJ, Kim J, O'Shea KM, O'Connell KA, Brown BH, Galvao T, Des Rosiers C, Polster BM, Hoppel CL, Stanley WC. Improved mitochondrial function with diet-induced increase in either docosahexaenoic acid or arachidonic acid in membrane phospholipids. PLoS One 7: e34402, 2012.
29. Laviolle B, Pape D, Turlin B, Bellissant E. Direct effects of 3 combinations of enalapril, metoprolol, and spironolactone on cardiac remodeling in dilated cardiomyopathic hamsters. J Card Fail 12: 752-758, 2006.
30. Mattera GG, Lo GP, Loi FM, Vanoli E, Gagnol JP, Borsini F, Carminati P. Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol 99: 33A-40A, 2007.
31. McLennan PL, Abeywardena MY, Dallimore JA, Raederstorff D. Dietary fish oil preserves cardiac function in the hypertrophied rat heart. Br J Nutr 108: 645-654, 2012.
32. Missihoun C, Zisa D, Shabbir A, Lin H, Lee T. Myocardial oxidative stress, osteogenic phenotype, and energy metabolism are differentially involved in the initiation and early progression of delta-sarcoglycan-null cardiomyopathy. Mol Cell Biochem 321: 45-52, 2009.
33. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 161: 915-919, 2011.
34. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei CL. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 57: 870-879, 2011.
35. O'Shea KM, Chess DJ, Khairallah RJ, Hecker PA, Lei B, Walsh K, Des Rosiers C, Stanley WC.-3 Polyunsaturated fatty acids prevent pressure overload-induced ventricular dilation and decrease in mitochondrial enzymes despite no change in adiponectin. Lipids Health Dis 9: 95, 2010.
36. 2+-induced permeability transition. J Mol Cell Cardiol 47: 819-827, 2009.
37. Sergiel JP, Martine L, Raederstorff D, Grynberg A, Demaison L. Individual effects of dietary EPA and DHA on the functioning of the isolated working rat heart. Can J Physiol Pharmacol 76: 728-736, 1998.
38. Shah KB, Duda MK, O'Shea KM, Sparagna GC, Chess DJ, Khairallah RJ, Robillard-Frayne I, Xu W, Murphy RC, Des Rosiers C, Stanley WC. The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: role of cardiac phospholipid remodeling. Hypertension 54: 605-611, 2009.
39. Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 148: 141-149, 1996.
40. Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN. Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol 42: 150-158, 2007.
41. Sharov VG, Todor AV, Imai M, Sabbah HN. Inhibition of mitochondrial permeability transition pores by cyclosporine A improves cytochrome C oxidase function and increases rate of ATP synthesis in failing cardiomyocytes. Heart Fail Rev 10: 305-310, 2005.
42. Shimizu T, Okamoto H, Chiba S, Matsui Y, Sugawara T, Akino M, Nan J, Kumamoto H, Onozuka H, Mikami T, Kitabatake A. VEGFmediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts. Cardiovasc Res 58: 203-212, 2003.
43. Shimizu T, Okamoto H, Chiba S, Matsui Y, Sugawara T, Onozuka H, Mikami T, Kumamoto H, Kitabatake A. Long-term combined therapy with an angiotensin type I receptor blocker and an angiotensin converting enzyme inhibitor prolongs survival in dilated cardiomyopathy. Jpn Heart J 43: 531-543, 2002.
44. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 237: 885-888, 1987.
45. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 34: 782-790, 1999.
46. Witte K, Schnecko A, Hauth D, Wirzius S, Lemmer B. Effects of chronic application of propranolol on beta-adrenergic signal transduction in heart ventricles from myopathic BIO TO2 and control hamsters. Br J Pharmacol 125: 1033-1041, 1998.
47. Zhu T, Zhou L, Mori S, Wang Z, McTiernan CF, Qiao C, Chen C, Wang DW, Li J, Xiao X. Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 112: 2650-2659, 2005.